Yuanda Pharmaceutical (00512) introduces the world's first adrenaline nasal spray to treat severe allergic reactions

Zhitong Finance App News, Yuanda Pharmaceutical (00512) issued an announcement. Recently, the Group reached a product cooperation agreement with Yuer Pharmaceutical Technology (Shanghai) Co., Ltd. (Yuer Pharmaceuticals). The Group will receive exclusive commercialization rights for the world's first adrenaline nasal spray Neffy® (Neffy®) for emergency treatment of adults and children aged 30 kg and above (2 mg specification) and 15-30 kg children (1 mg specification) for type I allergic reactions (including severe allergic reactions) within the cooperative channel in mainland China and non-exclusive commercialization rights in the Hong Kong Special Administrative Region of China. The cooperation is led by Yuanda Pharmaceutical (Beijing) Co., Ltd., a subsidiary of the Group located in Changping District, Beijing, and plans to achieve localized production within 24 months of product approval.

Yuer Pharmaceutical is a local innovative pharmaceutical company focusing on the field of pediatrics. It is committed to introducing and developing safe, effective, convenient and easy to use pediatric drugs for Chinese children. With deep experience in the field of pediatrics, it relies on global introduction and local two-wheel drive to help improve pediatric treatment plans in China and provide more innovative treatment options for Chinese pediatricians, patients and families.

This time, the Group introduced a globally innovative adrenaline nasal spray, the first non-injectable treatment product for type I allergic reactions approved by the FDA in 35 years. It is expected to improve the accessibility of adrenaline treatment products to patients with severe allergic reactions in China and fill the gap in the use of emergency medicine for severe allergic reactions outside of hospitals. After the product is launched, the Group will fully rely on the rich department resources and mature channel system accumulated in the field of first aid to accelerate its academic promotion and market education to help the product launch quickly. With its unique portability and ease of operation, YouSensitivity® is expected to quickly penetrate various out-of-hospital scenarios such as homes, schools, and travel, and become a new growth engine for the Group's cardiovascular first aid sector.

The cardiovascular emergency sector is one of the Group's key layout directions in the field of pharmaceutical technology, taking into account the two major directions of emergency rescue and chronic disease management. In the direction of first aid, as a “national basic drug production base”, a “national combat preparation reserve first aid drug manufacturer”, and a “national small variety drug (shortage drug) centralized production base construction unit”, the group has more than 30 varieties, of which 14 varieties are included in China's national emergency drug catalogue, 16 varieties are included in the shortage drug catalogue, and the number of product pipelines is among the highest in the industry. The products cover the three major emergency scenarios of in-hospital first aid, pre-hospital first aid and social first aid. Product portfolio. In the direction of chronic disease management, core products such as Nengqilang, Limeitong® eplerone tablets, and Hexinshuang/Hebeishuang continue to lead the market segment. Currently, the cardiovascular emergency sector is developing more than 20 products. Through a combination of independent innovation and research and breakthroughs in difficult imitation technology, it continues to lay out and develop clinically urgently needed cardiovascular first aid and chronic disease treatment products.

The Group has always attached great importance to research and development of innovative products and advanced technology, with patients' needs as the core, scientific and technological innovation as the core, increasing investment in innovative global products and advanced technology, enriching and improving product pipelines and industrial layout in response to unmet clinical needs, adopting a “global operation layout, dual cycle business development” strategy to form a new pattern of domestic and international dual cycle linkage development and mutual promotion, give full play to the Group's industrial advantages and R&D strength, and quickly launch innovative scientific and technological products on the market to provide patients around the world with more advanced and diverse treatment plans.